Responses and Toxicities of Risk-adapted Chemotherapy in Pediatric Intracranial Germ Cell Tumors.
- Author:
Dong Kil YOU
1
;
Soo Hyun LEE
;
Keon Hee YOO
;
Ki Woong SUNG
;
Do Hoon LIM
;
Hyung Jin SHIN
;
Hong Hoe KOO
Author Information
1. Department of Pediatrics, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. hhkoo@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
Intracranial germ cell tumor;
Chemotherapy;
Responses;
Toxicities
- MeSH:
Cisplatin;
Cyclophosphamide;
Diagnosis;
Drug Therapy*;
Etoposide;
Follow-Up Studies;
Germ Cells*;
Germinoma;
Hearing Loss, Sensorineural;
Hospitalization;
Humans;
Neoplasms, Germ Cell and Embryonal*;
Tinnitus;
Biomarkers, Tumor;
Vincristine
- From:Korean Journal of Pediatrics
2005;48(2):186-190
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study was to evaluate the responses and toxicities of risk-adapted chemotherapy in pediatric intracranial germ cell tumors(IC-GCT). METHODS: Fourteen patients who were diagnosed as IC-GCT from October 2002 to December 2003 received chemotherapy as an initial treatment modality. The low risk(LR) group was defined as follows: Pure germinoma and normal AFP level. Beta-hCG level 50 mIU/mL or less. The others belonged to the high risk(HR) group. Chemotherapy was composed of cisplatin, cyclophosphamide, etoposide and vincristine. Double doses of cisplatin and cyclophosphamide was used in HR patients. RESULTS: Pathologic confirmation was done in all but one. Median age at diagnosis was 11.6 yr (1.2-18.7 yr), and nine patients belonged to the HR group. Tumor markers were normalized after chemotherapy in all patients whose tumor markers had been elevated. Four LR patients(80 percent) and seven HR patients(77.8 percent) showed complete response(CR) at the end of chemotherapy. An additional two of the three patients with partial response(PR) achieved CR after radiation therapy (RT), and the remaining one relapsed before RT. Four LR and all HR patients experienced infectious episodes that required hospitalization. Four of the nine HR patients(44.4 percent) suffered from tinnitus, three of whom developed sensorineural hearing loss. All but one are surviving, event-free, with a median follow-up of 13.9 mo(8.1-22.3 mo). CONCLUSION: Risk-adapted cisplatin-based chemotherapy was effective even in HR patients, but regimen modification seems to be necessary to avoid an unacceptably high toxicity rate.
